Delving into the Latest Updates on Bone marrow-derived mesenchymal stromal cells(The University of Queensland) with Synapse

Overview

Basic Info

Drug Type

Mesenchymal stem cell therapy

Synonyms

bone marrow-derived mesenchymal stromal cells(The University of Queensland), Bone-marrow derived MSCs(The University of Queensland)

Target-

Mechanism

Cell replacements

Therapeutic Areas

Immune System Diseases

Active Indication

Allograft Rejection

Inactive Indication

Cardiomyopathy, DilatedCoronary Artery DiseaseDepressive Disorder+ [14]

Originator Organization

The University of Queensland

Active Organization

The University of Queensland

Inactive Organization

Academisch Ziekenhuis LeidenHospital General Universitario Gregorio Marañón

Emory University

+ [1]

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

This is a Phase 1/2 study to determine the safety and efficacy of allogeneic (third party), bone-marrow derived mesenchymal stromal cells (MSCs) for the treatment of Osteogenesis Imperfecta (OI) Type 3. It will evaluate this by looking at whether there are treatment related infusion reactions, and assessing linear growth rates and bone health, both of which are impaired in patients ages 3-10 with Osteogenesis Imperfecta Type 3. This is a single-site non-randomized clinical trial, that will take place at Children's Healthcare of Atlanta (CHOA) at Egleston and Emory Children's Center.

Start Date01 Sep 2024

Sponsor / Collaborator

Emory University

NCT05288725 / Not yet recruitingPhase 1/2

A Study to Evaluate the Safety, and Efficacy of Minimally Manipulated Autologous Bone Marrow Aspirate to Treat Knee Osteoarthritis in Patients

The study is a multicentered, randomized, double-blinded, placebo-controlled study conducted on the unilateral knee of 120 patients. The study compares the effectiveness of an injection of a mesenchymal stem cell preparation from autologous bone marrow aspirate (BMA) to a corticosteroid control for knee osteoarthritis. WOMAC, VAS pain scores, and MRI will be used for assessment. The study will be conducted at 3 sites in the United States.

Start Date01 Aug 2022

Sponsor / Collaborator-

ACTRN12620000840987 / RecruitingPhase 1IIT

Phase I trial on safety and tolerability of bone-marrow derived mesenchymal stromal cells (MSC) for deteriorating COVID-19 pneumonia

Start Date05 May 2020

Sponsor / Collaborator-

100 Clinical Results associated with Bone marrow-derived mesenchymal stromal cells(The University of Queensland)

Login to view more data

100 Translational Medicine associated with Bone marrow-derived mesenchymal stromal cells(The University of Queensland)

Login to view more data

100 Patents (Medical) associated with Bone marrow-derived mesenchymal stromal cells(The University of Queensland)

Login to view more data

4

Literatures (Medical) associated with Bone marrow-derived mesenchymal stromal cells(The University of Queensland)

01 Apr 2021·ERJ open research

Endobronchial autologous bone marrow–mesenchymal stromal cells in idiopathic pulmonary fibrosis: a phase I trial

Article

Author: Cordovilla, Rosa ; Villaron, Eva ; Nuñez-Córdoba, Jorge ; González-Ruiz, José María ; Andreu, Enrique ; Barrueco, Miguel ; Zulueta, Javier J ; Prósper, Felipe ; De-Torres, Juan ; Alcaide, Ana B ; Pueyo, Jesús ; Campo, Arantza ; Sanchez-Guijo, Fermín ; Ocón, María M

Rationale:

Idiopathic pulmonary fibrosis (IPF) has a dismal prognosis. Mesenchymal stromal cells (MSCs) have shown benefit in other inflammatory diseases.

Objectives:

To evaluate the safety and feasibility of endobronchial administration of bone marrow autologous MSCs (BM-MSC) in patients with mild-to-moderate IPF.

Methods:

A phase I multicentre clinical trial (ClinicalTrials.gov NCT01919827) with a single endobronchial administration of autologous adult BM-MSCs in patients diagnosed with mild-to-moderate IPF. In a first escalating-dose phase, three patients were included sequentially in three dose cohorts (10×106, 50×106 and 100×106 cells). In a second phase, nine patients received the highest tolerated dose. Follow-up with pulmonary function testing, 6-min walk test and St George's Respiratory Questionnaire was done at 1, 2, 3, 6 and 12 months, and with computed tomography at 3, 6 and 12 months.

Results:

21 bone marrow samples were obtained from 17 patients. Three patients were excluded from treatment due to chromosome aberrations detected in MSCs after culture, and one patient died before treatment. Finally, 13 patients received the BM-MSC infusion. No treatment-related severe adverse events were observed during follow-up. Compared to baseline, the mean forced vital capacity showed an initial decline of 8.1% at 3 months. The number of patients without functional progression was six (46%) at 3 months and three (23%) at 12 months.

Conclusions:

The endobronchial infusion of BM-MSCs did not cause immediate serious adverse events in IPF patients, but a relevant proportion of patients suffered clinical and/or functional progression. Genomic instability of BM-MSCs during culture found in three patients may be troublesome for the use of autologous MSCs in IPF patients.

01 Jan 2021·The Journal of biological chemistry

Withdrawal: Bone marrow stromal cell-derived growth inhibitor inhibits growth and migration of breast cancer cells via induction of cell cycle arrest and apoptosis

Article

Author: Wang, Tao ; Wang, Chunmei ; Chen, Taoyong ; Xia, Dajing ; Chen, Guoyou ; Li, Nan ; Wan, Tao ; Cao, Xuetao

01 Jun 2020·The Journal of biological chemistry

Expression of Concern: Bone marrow stromal cell-derived growth inhibitor inhibits growth and migration of breast cancer cells via induction of cell cycle arrest and apoptosis.

Article

100 Deals associated with Bone marrow-derived mesenchymal stromal cells(The University of Queensland)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Depressive Disorder	Phase 3	US	Emory University	28 Mar 2019
Genetic Diseases, Inborn	Phase 3	US	Emory University	28 Mar 2019
Inflammation	Phase 3	US	Emory University	28 Mar 2019
Osteoarthritis, Knee	Phase 3	US	Emory University	28 Mar 2019
Pain	Phase 3	US	Emory University	28 Mar 2019
Lung transplant rejection	Phase 2	AU	The University of Queensland	31 Mar 2020
Allograft Rejection	Phase 2	AU	The University of Queensland	21 Apr 2017
Fibrosis	Phase 2	NL	Academisch Ziekenhuis Leiden	31 Mar 2014
Kidney Failure, Chronic	Phase 2	NL	Academisch Ziekenhuis Leiden	31 Mar 2014
Opportunistic Infections	Phase 2	NL	Academisch Ziekenhuis Leiden	31 Mar 2014

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03818737 (MILES, CTgov)	Phase 3	Osteoarthritis, Knee	475	Bone Marrow Derived MSCs (Bone Marrow Derived MSCs)	cmxqadnher(tbyrkpuove) = rgxmdrhcrw maditqpowo (tjbxdtdupk, kneitraymb - enustanxid) View more	-	27 Jul 2023
				Adipose-derived MSCs (Adipose-derived MSCs)	cmxqadnher(tbyrkpuove) = esojxsokaw maditqpowo (tjbxdtdupk, kyfixtceqc - ddadcwywqu) View more
HOVON-113 (EHA2022) Manual	Phase 3	Steroid Refractory Graft Versus Host Disease	41	Mesenchymal stromal cell	rfutggopih(eqfkranrjs) = zfpibyoiqy owyfdvhzxj (lzvxxpuxdd ) View more	Negative	12 May 2022
				placebo	rfutggopih(eqfkranrjs) = jprtfudxfv owyfdvhzxj (lzvxxpuxdd ) View more